Pivotal Phase 3 Study of DAYVIGO™ (lemborexant) for the Treatment of Insomnia Disorder Published in JAMA Network Open

www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared DAYVIGO™ (lemborexant) to placebo and an active comparator in patients with insomnia disorder.1 In this study, DAYVIGO therapy significantly improved both sleep onset and sleep maintenance compared with placebo.Eisai logo”We are pleased to share these important study results in JAMA Network…

U.S. FDA Approves Eisai’s DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

here.1. About LemborexantLemborexant is a small-molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible…